Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Aflibercept (Primary) ; Sapanisertib (Primary)
- Indications Cancer; Glucagonoma; Insulinoma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 10 Feb 2016 Planned number of patients changed from 34 to 69, according to ClinicalTrials.gov record.
- 28 Apr 2015 Status changed from suspended to recruiting as per ClinicalTrials.gov record.